Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue to $243 Million, Cuts TRYNGOLZA Sales Guidance
Ionis Pharmaceuticals (IONS) reported Q3 2026 revenue of $243M, up 55% YoY. The company cut TRYNGOLZA sales guidance to $50M from $100M-$110M due to slower launch. Operating loss narrowed to $130M. DAWNZERA sales reached $37M in Q3. Ionis maintained full-year revenue guidance of $875M-$900M and expects to end 2026 with over $1.6B in cash.
How this was made
The 30-second read
Why it matters
The guidance reduction suggests weaker near‑term cash flow, likely prompting short‑term selling pressure.
Market read
Primary earnings release with a material guidance downgrade; high relevance for traders holding or shorting IONS.
What to watch
Royalty income from SPINRAZA and other partnered medicines may cushion earnings despite the TRYNGOLZA downgrade.
Background
Ionis Pharmaceuticals disclosed its Q3 earnings and revised sales outlook for its hypertriglyceridemia drug TRYNGOLZA.
Ticker impact
Ionis Pharmaceuticals reported Q3 2026 revenue of $243M and cut full-year TRYNGOLZA sales guidance to ~$50M, a new guidance downgrade.
downward pressure as investors price in lower TRYNGOLZA revenue
Revenue beat was modest and guidance for a key product was halved, which typically triggers sell‑offs in biotech stocks.
Market effects
Biotech sector may see broader risk‑off as guidance cuts raise concerns about product launch execution.
US biotech investors likely adjust exposure; limited impact outside US markets.
Modest; primarily affects US‑listed biotech investors.
Counterpoint
If the revenue beat and pipeline progress outweigh the guidance cut, the stock could rebound on long‑term growth expectations.
Key entities
- companyIonis Pharmaceuticals
US‑listed biotech (NASDAQ: IONS) reporting earnings and guidance.
